Literature DB >> 8482324

Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.

K Temma1, T Akera, A Chugun, H Kondo, K Hagane, S Hirano.   

Abstract

The cardiac actions of doxorubicin were compared with those of pirarubicin and aclarubicin to understand the mechanisms responsible for differences in cardiotoxic effects of anthracycline agents. In left atrial muscle preparations obtained from guinea-pig heart and stimulated at 2 Hz, anthracyclines produced positive inotropic effects. The magnitude of the effect was pirarubicin > doxorubicin > aclarubicin. The order for depression of potentiated postrest contraction and prolongation of the time to peak twitch tension was doxorubicin > pirarubicin > aclarubicin. Drug washout following a 2-h incubation with 100 microM doxorubicin prevented a further increase in the time to peak twitch tension, caused a marked recovery of depressed potentiated postrest contractions, and augmented the positive inotropic effect. Pirarubicin and doxorubicin, but not aclarubicin, caused a parallel rightward shift of the dose-response curve for the negative inotropic effect of acetylcholine. The potency of inhibition of [3H]quinuclidinyl benzilate binding was pirarubicin > doxorubicin > aclarubicin. These results indicate that three anthracycline anticancer agents share similar effects on cardiac muscle contractility and on muscarinic acetylcholine receptors. The actions of aclarubicin were weak compared to those of doxorubicin or pirarubicin. Increases in the time to peak twitch tension and the depression of potentiated postrest contraction are apparently mediated by mechanisms different from those responsible for the positive inotropic effects or antagonism at muscarinic acetylcholine receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482324     DOI: 10.1016/0014-2999(93)90951-d

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens.

Authors:  Takashi Kobayashi; Masayuki Kubota; Yoshiaki Kinoshita; Yuki Arai; Toshiyuki Oyama; Naoki Yokota; Koichi Saito; Yasunobu Matsuda; Mami Osawa
Journal:  Pediatr Surg Int       Date:  2019-09-26       Impact factor: 1.827

2.  Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

Authors:  G Minotti; M Parlani; E Salvatorelli; P Menna; A Cipollone; F Animati; C A Maggi; S Manzini
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

3.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes.

Authors:  Berend J van Meer; Ana Krotenberg; Luca Sala; Richard P Davis; Thomas Eschenhagen; Chris Denning; Leon G J Tertoolen; Christine L Mummery
Journal:  Nat Commun       Date:  2019-09-20       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.